
Boncare 150 mg
- Generic
- Ibandronic Acid
- Manufacturer
- Orion Pharma Ltd.
- Drug class
- Bisphosphonate preparations
Price
৳1,203.61 per 1 tablet kit
Packs & prices
- 1 tablet kit৳1,203.61
This is information only. Do not start, stop or switch medicines without a doctor's advice.
Warnings
Contraindications
Precautions
Physicians should be alert to any signs or symptoms signaling a possible esophageal reaction and patients should be instructed to discontinue Ibandronic Acid and seek medical attention if they develop dysphagia, odynophagia, retrosternal pain or new or worsening heartburn. While no increased risk was observed in controlled clinical trials there have been post-marketing reports of gastric and duodenal ulcers with oral bisphosphonate use, some severe and with complications. Since NSAIDs and bisphosphonates are both associated with gastrointestinal irritation, caution should be taken during concomitant medication with Ibandronic Acid. Osteonecrosis of the jaw (ONJ) has been reported in patients treated with bisphosphonates. Most cases have been in cancer patients undergoing dental procedures, but some have occurred in patients with postmenopausal osteoporosis or other diagnoses. Known risk factors for osteonecrosis of the jaw include a diagnosis of cancer, concomitant therapies (e.g., chemotherapy, radiotherapy, corticosteroids), and co-morbid disorders (e.g., anemia, coagulopathy, infection, pre-existing dental disease). Most reported cases have been in patients treated with bisphosphonates intravenously but some have been in patients treated orally. For patients who develop osteonecrosis of the jaw while on bisphosphonate therapy, dental surgery may exacerbate the condition. For patients requiring dental procedures, there are no data available to suggest whether discontinuation of bisphosphonate treatment reduces the risk of ONJ. Clinical judgment of the treating physician should guide the management plan of each patient based on individual benefit-risk assessment.
Side effects
Pregnancy & lactation
Nursing Mothers: Ibandronic Acid should not be used during lactation. In lactating rats treated with 0.08 mg/kg/day IV. ibandronic acid, the highest concentration of ibandronic acid in breast milk was 8.1 ng/ml and was seen in the first 2 hours after i.v. administration. After 24 hours, the concentration in milk and plasma was similar, and corresponded to about 5 % of the concentration measured after 2 hours.
Drug interactions
In relation to disposition, no drug interactions of clinical significance are considered likely, since ibandronic acid does not inhibit the major human hepatic P450 isoenzymes and has been shown not to induce the hepatic cytochrome P450 system in rats. Furthermore, plasma protein binding is low at therapeutic concentrations and ibandronic acid is therefore unlikely to displace other drugs. Ibandronic acid is eliminated by renal excretion only and does not undergo any biotransformation. The secretory pathway appears not to include known acidic or basic transport systems involved in the excretion of other drugs. In a one-year study in postmenopausal women with osteoporosis (BM16549). the incidence of upper gastrointestinal events in patients concomitantly taking aspirin or NSAIDs was similar in patients taking Ibandronic Acid 2.5 mg daily or 150mg once monthly. Of over 1500 patients enrolled in study BM 16549 comparing monthly with daily dosing regimens of ibandronic acid, 14% of patients used histamine (H2) blockers or proton pump inhibitors. Among these patients, the incidence of upper gastrointestinal events in the patients treated with Ibandronic Acid 150 mg once monthly was similar to that in patients treated with Ibandronic Acid 2.5 mg daily.
More information
Indications
Treatment of Osteoporosis: Osteoporosis may be confirmed by the finding of low bone mass (T-score <-2.0 SD) and the presence or history of osteoporotic fracture, or a low bone mass (T-score <-2.5 SD) in the absence of documented pre-existing osteoporotic fracture.
Dosage
- Tablets should be swallowed whole with a full glass of plain water (180 to 240 ml) while the patient is sitting or standing in an upright position. Patients should not lie down for 60 minutes after taking Ibandronic acid.
- Plain water is the only drink that should be taken with Ibandronic acid. Please note that some mineral waters may have a higher concentration of calcium and therefore should not be used.
- Patients should not chew or suck the tablet because of a potential for oropharyngeal ulceration. Patients should receive supplemental calcium or vitamin D if dietary intake is inadequate. In case a once-monthly dose is missed, patients should be instructed to take one Ibandronic Acid 150 mg tablet the morning after the tablet is remembered unless the time to the next scheduled dose is within 7 days. Patients should then return to taking their dose once a month on their originally scheduled date. If the next scheduled dose is within 7 days, patients should wait until their next dose and then continue taking one tablet once a month as originally scheduled. Patients should not take two 150 mg tablets within the same week.
Use in children
Patients with hepatic impairment: No dosage adjustment is necessary.
Elderly: No dosage adjustment is necessary. Children: Safety and efficacy have not been established in patients less than 18 years old.
Overdose
Pharmacology
Ibandronic acid is a highly potent bisphosphonate belonging to the nitrogen-containing group of bisphosphonates, which act on bone tissue and specifically inhibit osteoclast activity, It does not interfere with osteoclast recruitment. The selective action of ibandronic acid on bone tissue is based on the high affinity of this compound for hydroxyapatite, which represents the mineral matrix of the bone. Ibandronic acid reduces bone resorption, with no direct effect on bone formation. In postmenopausal women, it reduces the elevated rate of bone turnover towards premenopausal levels, leading to a progressive net gain in bone mass. Daily or intermittent administration of ibandronic acid results in reduced bone resorption as reflected in reduced levels of serum and urinary biochemical markers of bone turnover, increased BMD and a decreased incidence of fractures.
Therapeutic class
Storage
Source: medex.com.bd · Prescribing information (PDF)
Cheaper alternatives
Same generic, strength and form — sorted by price
BondrixCheapest
Ibn Sina Pharmaceuticals Ltd.
৳400 / 1 tablet kit
৳803.61 less (67%)
Bone-Guard
Incepta Pharmaceuticals Ltd.
৳510 / 1 tablet kit
৳693.61 less (58%)
Bonmax
Globe Pharmaceuticals Ltd.
৳510 / 1 tablet kit
৳693.61 less (58%)
Maxbon
Square Pharmaceuticals Ltd.
৳510 / 1 tablet kit
৳693.61 less (58%)
Ostiban
Eskayef Pharmaceuticals Ltd.
৳510 / 1 tablet kit
৳693.61 less (58%)
SB-Iban
Sunman-Birdem Pharma Ltd.
৳510 / 1 tablet kit
৳693.61 less (58%)
Droniva
Navana Pharmaceuticals Ltd.
৳700 / 1 tablet kit
৳503.61 less (42%)
Ivana
Renata Limited
৳995 / 1 tablet kit
৳208.61 less (17%)
Ibandron
Aristopharma Ltd.
৳1,000 / 1 tablet kit
৳203.61 less (17%)
Bonfix
Opsonin Pharma Ltd.
৳1,200 / 1 tablet kit
৳3.61 less (0%)
Bonaid
Labaid Pharma Ltd.
৳1,500 / 1 tablet kit
৳296.39 more
Osteonil
Innovative Pharma (Albion)
৳1,770 / 1 tablet kit
৳566.39 more
Bondrova
Healthcare Pharmaceuticals Ltd.
৳1,960 / 1 tablet kit
৳756.39 more
Bonova
Radiant Pharmaceuticals Ltd.
৳2,507.52 / 1 tablet kit
৳1,303.91 more
Bottle/tube prices depend on size — compare quantities before switching.